{
    "clinical_study": {
        "@rank": "83930", 
        "arm_group": [
            {
                "arm_group_label": "LEO 39652 cream", 
                "arm_group_type": "Experimental", 
                "description": "Active drug"
            }, 
            {
                "arm_group_label": "LEO 39652 cream vehicle", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo drug"
            }
        ], 
        "brief_summary": {
            "textblock": "The principle aim of this study is to obtain safety, tolerability and pharmacokinetic data\n      when LEO 39652 cream is administered cutaneously as single dose to subjects with atopic\n      dermatitis and to healthy subjects."
        }, 
        "brief_title": "Safety, Tolerability and Pharmacokinetics in AD Subjects and Healthy Subjects of Cutaneous Application of LEO 39652 Cream", 
        "completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Atopic Dermatitis", 
        "condition_browse": {
            "mesh_term": [
                "Dermatitis", 
                "Dermatitis, Atopic"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Healthy subjects or subjects with AD as defined by the Hanifen and Rajka criteria and\n             with at least mild disease activity (IGA >2) for the whole body\n\n          -  AD lesions amenable to cutaneous treatment located on the trunk and/or limbs (only\n             for AD subjects)\n\n          -  Male subjects aged between 18 and 65 years with a body mass index (BMI) between 19.0\n             and 32.0 kg/m2 inclusive\n\n        Exclusion Criteria:\n\n          -  Subjects who currently suffer from, or show signs of eczema or other skin lesions\n             (only for healthy subjects)\n\n          -  Subjects who are still participating in a clinical trial (e.g. attending follow-up\n             visits) or who have participated in a clinical study involving administration of an\n             investigational product or a marketed drug product within the past 3 months prior to\n             the first dosing occasion.\n\n          -  Subjects with known immunocompromised state due to treatment with immunosuppressive\n             drugs or due to history of a disease leading to immunocompromised status.\n\n          -  History of or current cardiac arrhythmic disorder\n\n          -  Subjects with a current active malignancy or a history of malignancy in remission for\n             less than 5 years except excised skin (not melanoma) and cervical cancer.\n\n          -  Subjects who have any clinically significant allergic disease (excluding non- active\n             hayfever) as determined by the Investigator"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "26", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 7, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01850849", 
            "org_study_id": "LP0083-1011"
        }, 
        "intervention": [
            {
                "arm_group_label": "LEO 39652 cream", 
                "intervention_name": "LEO 39652 cream", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "LEO 39652 cream vehicle", 
                "intervention_name": "cream vehicle", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "No", 
        "lastchanged_date": "January 7, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Leeds", 
                        "country": "United Kingdom", 
                        "zip": "LS2 9LH"
                    }, 
                    "name": "Covance Clinical Research Unit, Hyde Street, Leeds, UK"
                }, 
                "investigator": {
                    "last_name": "Joseph Chiesa, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Richard Fitzgerald, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Liverpool", 
                        "country": "United Kingdom", 
                        "zip": "L7 8XP"
                    }, 
                    "name": "Covance Royal Liverpool Clinical Research Unit"
                }, 
                "investigator": {
                    "last_name": "Richard Fitzgerald, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United Kingdom"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase I, First-in-Human, Vehicle Controlled, Single Ascending Dose Trial Evaluating the Safety, Tolerability and Pharmacokinetics in Male Subjects With AD and in Healthy Male Subjects of Cutaneous Application of LEO 39652 Cream", 
        "overall_contact": {
            "email": "rikke.fischer@leo-pharma.com", 
            "last_name": "Rikke L Fischer, ICTM", 
            "phone": "+4544945888"
        }, 
        "overall_official": {
            "affiliation": "Covance Clinical Research Unit, Hyde Street, Leeds, UK", 
            "last_name": "Joseph Chiesa, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United Kingdom: Medicines and Healthcare Products Regulatory Agency", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Number of subjects with adverse events and change from baseline in vital signs (blood pressure, pulse rate) ECG, clinical laboratory and local tolerability assessments", 
            "safety_issue": "Yes", 
            "time_frame": "Up to 48 hours after dosing"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01850849"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "LEO 39652 and metabolites in blood", 
            "safety_issue": "Yes", 
            "time_frame": "Up to 48 hours after dosing"
        }, 
        "source": "LEO Pharma", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "LEO Pharma", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)", 
        "study_type": "Interventional", 
        "verification_date": "April 2013"
    }
}